Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study
PLOS One · 2025
DOI: 10.1371/journal.pone.0323880 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS One, 2025. Verfasst von Chae Won Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, CHA University School of Medicine, Seongnam, Republic of Korea. Hauptthemen laut MEDLINE: Liver Cirrhosis, Drug Repositioning, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea government Ministry of Science and ICT, The National Research Foundation of Korea, Korea University.
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major risk factor for liver cirrhosis, yet effective prevention or treatment strategies remain limited. To address this, we utilized a signature-based in silico drug repositioning approach to identify potential therapeutics for MASLD that may reduce the risk of cirrhosis.
Methods
We analyzed gene expression datasets to identify differentially expressed genes (DEGs) in MASLD and matched them to candidate drugs using L1000CDS2. We further validated potential drugs by cross-referencing with prescription data from the Korea National Health Insurance Service (NHIS). Participants who underwent health screenings between 2013 and 2014 were included. MASLD was diagnosed in individuals with hepatic steatosis (fatty liver index ≥60) and at least one cardiometabolic risk factor.
Results
We identified 11 drug candidates and analyzed 49,555 MASLD patients (mean age: 63.0 years, SD: 8.6). Atenolol (SHR: 0.81; 95% CI: 0.72–0.92; P < 0.001), isosorbide dinitrate (SHR: 0.82; 95% CI: 0.73–0.93; P = 0.001), and valsartan (SHR: 0.52; 95% CI: 0.45–0.60; P < 0.001) were associated with a reduced risk of cirrhosis. Conversely, amlodipine-based combinations (SHR: 1.24; 95% CI: 1.11–1.39; P < 0.001), torasemide (SHR: 1.39; 95% CI: 1.24–1.56; P < 0.001), and valsartan-based combinations (SHR: 1.22; 95% CI: 1.09–1.37; P < 0.001) were linked to an increased risk.
Conclusions
Our findings suggest that antihypertensive drugs such as atenolol and isosorbide dinitrate may protect MASLD patients from cirrhosis, providing valuable insights for clinical applications and treatment strategies.
Limitations
This study is limited to drugs registered in the Korean NHIS, potentially excluding other relevant candidates. Additionally, the absence of dietary and genetic data in the NHIS database may introduce residual confounding. Lastly, as the study population consists solely of Korean adults, the findings may not be generalizable to other populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Biomedical Informatics, CHA University School of Medicine, Seongnam, Republic of Korea.
- Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Chae Won Lee
Förderung
- Korea government Ministry of Science and ICT
- The National Research Foundation of Korea
- Korea University
Zitieren
APA
Lee, C. W., Kang, E. S., Jeong, S., & Han, H. W. (2025). Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study. PLOS One. https://doi.org/10.1371/journal.pone.0323880
Vancouver
Lee CW, Kang ES, Jeong S, Han HW. Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study. PLOS One. 2025. doi:10.1371/journal.pone.0323880
BibTeX
@article{Lee2025,
author = {Lee, Chae Won and Kang, Eun Seok and Jeong, Seogsong and Han, Hyun Wook},
title = {Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0323880}
}
EUVIMED